Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Long-term follow-up of antivascular endothelial growth factor treatment for diabetic macular oedema: a four-year real-world study
Stockholms universitet, Samhällsvetenskapliga fakulteten, Statistiska institutionen. Uppsala University, Sweden.ORCID-id: 0000-0003-3691-8326
Visa övriga samt affilieringar
Antal upphovsmän: 72020 (Engelska)Ingår i: Acta Ophthalmologica, ISSN 1755-375X, E-ISSN 1755-3768, Vol. 98, nr 4, s. 360-367Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Purpose: To evaluate visual acuity (VA) and central retinal thickness (CRT) on optical coherence tomography during a 4-year period in patients treated for sight-threatening diabetic macular oedema (DMO) at two Swedish county hospitals. Additionally, to compare health-related quality of life and subjective visual functioning before and after 4 years of treatment.

Methods: Fifty-eight patients with DMO were evaluated after 4 years of antivascular endothelial growth factor (VEGF) treatment. VA, CRT and clinical data were retrospectively reviewed. Health-related quality of life and subjective visual functioning were evaluated with Short Form Health Survey (SF-36) and National Eye Institute Vision Functioning Questionnaire 25 (VFQ-25). Comparisons between independent groups were performed using Pearson's chi(2) test, Fisher's exact test or Mann-Whitney U test. Spearman's rho was used for correlation analyses. Wilcoxon signed-rank test was used for comparison between dependent groups. Logistic regression analysis was applied for analysis of VA and CRT over 4 years.

Results: Follow-up data were obtained from 37 of 58 (63.8%) patients. Baseline characteristics were similar, regardless of follow-up. VA improvement at 1 year (mean + 4.4, SD 7.5; ETDRS letter score) was maintained over 3 years, then declined. CRT was reduced throughout the study. In the first treatment year, eyes received 5.1 (1.4) anti-VEGF injections, followed by approximately two injections yearly. Additional treatment included laser and dexamethasone implants. SF-36 showed no change at 4 years, compared with baseline. VFQ-25 demonstrated improvement in near vision activities (p = 0.036).

Conclusion: Significant long-term improvement in visual function was present in patients with anti-VEGF-treated DMO.

Ort, förlag, år, upplaga, sidor
2020. Vol. 98, nr 4, s. 360-367
Nyckelord [en]
anti-VEGF treatment, diabetic macular oedema, longitudinal study, long-term follow-up, real-world study, visual acuity
Nationell ämneskategori
Oftalmologi
Identifikatorer
URN: urn:nbn:se:su:diva-175750DOI: 10.1111/aos.14290ISI: 000492664100001PubMedID: 31656056OAI: oai:DiVA.org:su-175750DiVA, id: diva2:1382421
Tillgänglig från: 2020-01-03 Skapad: 2020-01-03 Senast uppdaterad: 2022-02-26Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMed

Person

Rosenblad, Andreas

Sök vidare i DiVA

Av författaren/redaktören
Rosenblad, Andreas
Av organisationen
Statistiska institutionen
I samma tidskrift
Acta Ophthalmologica
Oftalmologi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 16 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf